Author Correction: interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC (Nature Cancer, (2023), 4, 6, (860-871), 10.1038/s43018-023-00578-z)

Authors
Category Primary study
JournalNATURE CANCER
Year 2024
This article has no abstract
Epistemonikos ID: 3f951200a51dc2c02568eb0f1e66a6477671d8b6
First added on: Jan 07, 2024